NEW YORK (360Dx) – BioAffinity Technologies today said that it has inked a licensing agreement with Precision Pathology Services for the continued development and commercial sale of its CyPath Lung assay as a laboratory-developed test used for the diagnosis of early-stage lung cancer.

BioAffinity President and CEO Maria Zannes said that Precision Pathology will develop the test as an LDT for commercial sale by the first-quarter of 2019.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.